| Autor: |
Roberto Iacovelli, Daniela Arduini, Chiara Ciccarese, Francesco Pierconti, Alessandro Strusi, Geny Piro, Carmine Carbone, Nazario Foschi, Gennaro Daniele, Giampaolo Tortora |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Critical reviews in oncology/hematology. 176 |
| ISSN: |
1879-0461 |
| Popis: |
Hereditary and sporadic renal cell carcinomas (RCCs) are often associated with Von Hippel-Lindau (VHL)-gene inactivation. Patients with VHL disease have an increased risk of RCC, leading to bilateral nephrectomy and dialysis. In patients with advanced RCC, no standard second-lines are available after progression to immune checkpoint inhibitors (ICIs), and new agents are required to manage progression. HIFs have emerged as a promising target for metastatic RCC patients who have progressed to ICI-based combinations, as well as for those with RCC and VHL syndrome where the goal is to delay surgery and/or and preserve kidney function and avoid dialysis. This review describes the available evidence supporting the use of the small-molecule HIF-2 alpha inhibitor, belzutifan (MK-6482), as well as other new anti-HIF molecules that have demonstrated significant efficacy in VHL disease-related RCCs as well as for sporadic RCC that has progressed after the use of ICI-based combinations. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect